pipette
ESEspañol

Plasma Proteomic Classification of Alzheimer Disease, Parkinson Disease, and Amyotrophic Lateral Sclerosis Using a Single Neurodegeneration Panel: A Diagnostic Cohort Study

K. Okada, S. Shimohama, R. Okochi, S. Bun, K. Takahata, H. Tabuchi, Y. Iwabuchi, T. Tezuka, T. Nukariya, S. Okusa, Y. Nihei, S. Morimoto, S. Takahashi, K. Tai, Y. Sato, J. Kuromitsu, J. Nakahara, M. Seki, H. Okano, M. Mimura, D. Ito

PreprintReal-world use

In the authors' words

Importance: Blood biomarkers for Alzheimer disease(AD), Parkinson disease(PD), and amyotrophic lateral sclerosis(ALS) are typically developed as disease-specific single-analyte tests. Whether one shared plasma panel can support disease-selective classification remains unclear. Objective: To test whether the Olink Target 48 Neurodegeneration plasma panel, analyzed with disease-specific Elastic Net models, can discriminate AD, PD, and ALS in a heterogeneous neurological cohort. Design, Setting, and Participants: Single-center diagnostic cohort study at Keio University Hospital, Tokyo, Japan. After quality control and one consent withdrawal, 302 participants were analyzed(healthy controls n = 62; AD continuum n = 93; PD n = 39; ALS n = 27; other neurological disorders n = 81) and allocated by diagnosis-stratified sampling into a discovery training set(n = 211) and a locked hold-out test set(n = 91). Exposures: Plasma normalized protein expression from 42 assays retained after protein quality control. Plasma DOPA decarboxylase was excluded a priori from all classifiers because blood levels primarily reflect dopaminergic treatment exposure. Main Outcomes and Measures: Hold-out receiver operating characteristic area under the curve(AUC). Sensitivity and specificity at a training-set Youden threshold locked for Test. Results: Hold-out AUCs were 0.974(95% CI, 0.942-0.995) for AD, 0.926(0.820-1.000) for PD, and 0.995(0.980-1.000) for ALS. At locked Youden cutoffs, sensitivity was 0.929 (95% CI, 0.765-0.991) and specificity was 0.921 (95% CI, 0.824-0.974) for AD, 0.833 (95% CI, 0.516-0.979) and 0.975 (95% CI, 0.912-0.997) for PD, and 1.000 (95% CI, 0.631-1.000) and 0.940 (95% CI, 0.865-0.980) for ALS. Conclusions and Relevance: A single plasma neurodegeneration panel supported disease-selective classification of AD, PD, and ALS in internal validation. Multicenter external validation is needed before clinical application.

Main resultLimitation the authors admit

Appeared: Thursday, October 22. medRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.10.19.26365782